Key result
Biaromatic Nav1.5 blockers like ranolazine treat stable angina and VT by reducing action potential recovery.
Why the study?
This review was conducted to analyze compounds with cardioprotective properties among biaromatic structures, focusing on sodium channel blockers.
Biaromatic sodium channel blockers, including ranolazine, demonstrate cardioprotective properties by modulating Nav1.5 late currents, offering therapeutic benefits for stable angina and ventricular tachycardia.
May support adjunctive use in stable angina and VT; leaves open prospective RCTs for biaromatic Nav1.5 blockers.
This review continues a series of reviews on the analysis of compounds with cardioprotective properties in a number of biaromatic structures, which include a range of sodium channel blockers. Among voltage-gated sodium channels, the Nav1.5 isoform is the most abundant in the heart. Sodium channel blockers have historically been called "class I antiarrhythmics". Among the compounds of this type, a biaromatic structure mainly have the Nav1.5 late current blockers belonging to the Id subclass of antiarrhythmic drugs. Leader molecules from this subgroup, such as ranolazine, GS-458967, and F15845, reduce action potential recovery time and suppress trigger activity induced by early post-depolarization. They are effective for the treatment of stable angina and ventricular tachycardia.
No takes yet. Share an insight, caveat, or question.
Г. В. Мокров (2022) conducted a review in Stable angina and ventricular tachycardia. Sodium channel blockers (ranolazine, GS-458967, F15845) was evaluated. Nav1.5 late sodium current blockers with a biaromatic structure, such as ranolazine, reduce action potential recovery time and are effective for stable angina and ventricular tachycardia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: